Brokerage firm Rodman & Renshaw Assumes its rating on Capricor Therapeutics Inc(CAPR). In a research note issued to the investors, the brokerage major Announces the price-target to $14 per share. The shares have been rated Buy. The rating by the stock financial advisor at Rodman & Renshaw was issued on Feb 13, 2017 in a research report to their Investors and Clients.
Capricor Therapeutics Inc (CAPR) made into the market gainers list on Wednesdays trading session with the shares advancing 0.97% or 0.03 points. Due to strong positive momentum, the stock ended at $3.12, which is also near the day’s high of $3.3358. The stock began the session at $3.17 and the volume stood at 29,196 shares. The 52-week high of the shares is $5.4 and the 52 week low is $1.91. The company has a current market capitalization of $67 M and it has 2,13,99,019 shares in outstanding.
Capricor Therapeutics Inc(CAPR) last announced its earnings results on Nov 10, 2016 for Fiscal Year 2016 and Q3.Earnings per share were $-0.29.
Several Insider Transactions has been reported to the SEC. On Sep 22, 2016, Sinai Medical Center Cedars (10% owner) purchased 312,500 shares at $3.20 per share price.Also, On Mar 21, 2016, Linda Marban (CEO) purchased 10,152 shares at $2.40 per share price.On Mar 21, 2016, Anthony Bergmann (Vice President of Finance) purchased 2,030 shares at $2.40 per share price, according to the Form-4 filing with the securities and exchange commission.
Capricor Therapeutics Inc. is a development-stage biopharmaceutical company. The Company develops and commercializes regenerative medicine and large molecule products for the treatment of disease with a primary focus on cardiovascular diseases. The Company has six drug candidates in stages of development which include CAP-1002 CAP-1001 CSps Exosomes Cenderitide (CD-NP) and CU-NP. The Company’s technology is based in cardiospheres (CSps) which are multi-cell clusters of cardiac derived cells. The Company’s product candidate the cardiosphere-derived cells (CDC) is the single cell monolayer product of the CSps. Both CSps and CDCs are derived from a deceased human donor (allogeneic source) or from heart tissue taken directly from recipient patients themselves (autologous source).